MAPT and myeloid sarcoma: To assist with diagnosis, CSF analysis for AD biomarkers versus amyloid PET can be considered to assess for comorbid AD pathology that can coexist with MS, with the caveat that the MS disease process may also interact with Aβ and tau, thus affecting the interpretation of the test results.